pharma · Metastatic castration-resistant prostate cancer. · short-term treatment of insomnia
Orion Laboratories Pty
Orion Laboratories Pty.
Orion Laboratories is a pharma organization headquartered in Baton Rouge, USA. Primary therapeutic focus areas include Metastatic castration-resistant prostate cancer., short-term treatment of insomnia, Parkinson desease
Baton Rouge, USA HQ
2008 Founded
52 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Baton Rouge, USA
- Founded
- 2008
- Employees
- 52
- Programs
- 9
- Drugs
- 20
- Patents
- 0
SENS-401 (R-Azasetron Besylate)
Phase 2 · small molecule · Hearing Loss
SENS-401 (R-Azasetron Besylate) for Hearing Loss is a Phase 2 program (small_molecule) at Orion Laboratories Pty. with 1 ClinicalTrials.gov record(s).
Internal code SENS-401-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Orion Laboratories Pty.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hearing Loss
- Status
- completed
- Trials
- 1